Sugi Predict

Sugi Predict / Targets / TERF2IP

TERF2IP

Telomeric repeat-binding factor 2-interacting protein 1 · Q9NYB0 · TERF2IP on Sugi Atlas →

1,347 patent compounds predicted against TERF2IP, 1,099 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16480282 SCHEMBL16480282 0.50 12/20
SCHEMBL16480284 SCHEMBL16480284 0.49 12/20
SCHEMBL19386878 SCHEMBL19386878 0.38 12/20
SCHEMBL19386877 SCHEMBL19386877 0.36 12/20
SCHEMBL20366249 SCHEMBL20366249 0.39 11/20
SCHEMBL19386874 SCHEMBL19386874 0.38 11/20
SCHEMBL19386940 SCHEMBL19386940 0.38 11/20
SCHEMBL19386844 SCHEMBL19386844 0.37 11/20
SCHEMBL19386929 SCHEMBL19386929 0.35 11/20
SCHEMBL17882233 SCHEMBL17882233 0.34 10/20
SCHEMBL19386870 SCHEMBL19386870 0.34 10/20
SCHEMBL14028880 SCHEMBL14028880 0.46 9/20
SCHEMBL21474003 SCHEMBL21474003 0.46 8/20
SCHEMBL21335274 SCHEMBL21335274 0.40 8/20
SCHEMBL14240951 SCHEMBL14240951 0.40 8/20
SCHEMBL17882070 SCHEMBL17882070 0.34 8/20
SCHEMBL19386839 SCHEMBL19386839 0.34 8/20
SCHEMBL14028877 SCHEMBL14028877 0.44 7/20
SCHEMBL17992399 SCHEMBL17992399 0.43 7/20
SCHEMBL21335210 SCHEMBL21335210 0.43 7/20

Clinical trials — most relevant to TERF2IP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Low-Dose Danazol for the Treatment of Telomere Related Diseases PHASE2COMPLETED
Nandrolone Decanoate in the Treatment of Telomeropathies PHASE1/PHASE2COMPLETED
Danazol for Genetic Bone Marrow and Lung Disorders PHASE1/PHASE2COMPLETED
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma PHASE1WITHDRAWN
Nucleoside Therapy in Patients With Telomere Biology Disorders PHASE1RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Telomere and Telomerase nanWITHDRAWN
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants nanRECRUITING
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma nanUNKNOWN
Telomere Repair Gene Mutation in Inflammatory Bowel Disease nanCOMPLETED
Body Awareness and Aerobic Exercise: Telomere Impact nanCOMPLETED
Telomere Disclosure and Impact on Psychological Distress and Health Behaviors nanCOMPLETED
Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique nanUNKNOWN
Vascular Senescence and Atherosclerotic Plaque Vulnerability nanRECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Biocollection in MyeloDysplastic Syndrome (P-MDS) nanRECRUITING
Nasal Brushing for the Diagnosis and Understanding of Telomeropathies nanUNKNOWN
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals nanUNKNOWN
Aerobic Exercise and Telomere Length in Patients With Heart Failure. nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Mitochondrial DNA Copy Number and Leukocyte Telomere Length as Biomarkers in Type 2 Diabetic Patients nanUNKNOWN
Telomerase Activator and Retinal Amyloid nanCOMPLETED
Influence of Prostate Cancer Radiation on Aging nanCOMPLETED
Chromosomal Translocations in Chandigarh Police nanCOMPLETED
Natural History of Acquired and Inherited Bone Marrow Failure Syndromes nanRECRUITING
Impact of Bariatric and Metabolic Surgery on the Reduction of Premature Aging. nanCOMPLETED
Anti-age Dietary Supplements in Healthy Older Adults: the proBNPage Reduction Trial nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TERF2IP binder may also engage these)

ProteinNameSimilarity
Q4R4I0 — 1.000 Q4R4I0 →
Q0VCT3 — 1.000 Q0VCT3 →
Q91VL8 — 0.996 Q91VL8 →
Q5EAN7 — 0.993 Q5EAN7 →
O54935 — 0.982 O54935 →
A4FV61 — 0.980 A4FV61 →
Q496Y0 — 0.980 Q496Y0 →
P49797 — 0.979 P49797 →
P12755 — 0.979 P12755 →
A4D2P6 — 0.978 A4D2P6 →
Q9H467 — 0.978 Q9H467 →
Q60698 — 0.977 Q60698 →
NOM1 Nucleolar MIF4G domain-containing protein 1 0.977 landscape →
Q7TN31 — 0.977 Q7TN31 →
Q8C2A2 — 0.977 Q8C2A2 →
Q99MU3 — 0.977 Q99MU3 →
Q9TUG2 — 0.977 Q9TUG2 →
Q8C190 — 0.976 Q8C190 →
Q7T0L4 — 0.976 Q7T0L4 →
Q5RF77 — 0.976 Q5RF77 →
Q60596 — 0.976 Q60596 →
PML Protein PML 0.976 landscape →
P97492 — 0.976 P97492 →
Q5R6F3 — 0.976 Q5R6F3 →
Q14202 — 0.976 Q14202 →
Q8NFZ0 — 0.975 Q8NFZ0 →
Q6DVA0 — 0.975 Q6DVA0 →
Q9WU40 — 0.975 Q9WU40 →
Q8WY91 — 0.975 Q8WY91 →
P18887 — 0.975 P18887 →